MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
May 7, 2009
Brian Orelli
Derailed and Built to Stay That Way Investors aren't happy with Biovail's plan to get back on track. mark for My Articles similar articles
The Motley Fool
October 29, 2007
Brian Orelli
The Extended Release That Wasn't The FDA is investigating Teva's generic version of Wellbutrin XL. Investors, take note. mark for My Articles similar articles
The Motley Fool
November 21, 2007
Brian Orelli
Depression Hits Biovail An FDA decision on Biovail's depression drug could be another six months away. mark for My Articles similar articles
The Motley Fool
September 23, 2008
Brian Orelli
Extended Look at an Extended-Release Drug The FDA is still investigating Teva's generic Wellbutrin XL. mark for My Articles similar articles
The Motley Fool
March 3, 2004
Alyce Lomax
Biovail Gets Nailed... Again The Canadian drug maker's stock falls on downbeat guidance. mark for My Articles similar articles
The Motley Fool
March 16, 2007
Billy Fisher
Challenge Awaits Biovail The company's popular Wellbutrin XL will be facing generic competition soon. Biovail is currently trading 36% below its 52-week high. mark for My Articles similar articles
The Motley Fool
November 13, 2006
Brian Lawler
Biovail Is Getting Cheap One of the drugmaker's products could face generic competition in the next year. Investors, take note. mark for My Articles similar articles
Chemistry World
October 5, 2012
Phillip Broadwith
Teva pulls generic antidepressant The move was prompted by an FDA investigation into whether the generic version (Budeprion XL, made by Impax and marketed by Teva) is truly therapeutically equivalent to the branded medicine (Wellbutrin XL). mark for My Articles similar articles
The Motley Fool
August 3, 2007
Brian Orelli
Watson Turns It Around The pharmaceutical's steady revenue growth results in positive income for the quarter. Investors, take note. mark for My Articles similar articles
The Motley Fool
November 26, 2010
Brian Orelli
Black Friday Biotech Bargains Drugmakers on sale. mark for My Articles similar articles
The Motley Fool
December 11, 2006
Brian Lawler
Biovail Gives Investors the Cash Regardless of lower forward estimates, though, it's nice to see a mature biotech rewarding shareholders, and if Biovail can sustain its dividend over the long run, it will be by far the highest-yielding mid-cap pharma stock. mark for My Articles similar articles
The Motley Fool
August 28, 2007
Brian Orelli
Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note. mark for My Articles similar articles
The Motley Fool
January 19, 2011
Brian Orelli
A Painfully Protracted Partner Depomed is in a bind. mark for My Articles similar articles
The Motley Fool
December 26, 2007
Brian Orelli
Teva's Heartburning Battle Teva launches its generic version of Wyeth's and Altana's heartburn medication, Protonix; those companies attempt to get a preliminary injunction. There are high stakes on both sides of the dispute. mark for My Articles similar articles
The Motley Fool
July 30, 2008
Brian Orelli
Teva Has Revenue in All the Wrong Places Sometimes double-digit growth isn't all it's cracked up to be. For generic-drug maker Teva Pharmaceuticals, the growth wasn't quite as exciting as the company's top line might suggest. mark for My Articles similar articles
The Motley Fool
August 3, 2004
Jeff Hwang
Generics Pump Watson The firm's strong growth in generic drug sales eases its branded product pains. The stock is up more than 10%. mark for My Articles similar articles
The Motley Fool
September 9, 2010
Jim Mueller
Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker. mark for My Articles similar articles
The Motley Fool
November 7, 2008
Brian Orelli
Teva's Steady Growth Generic-drug maker Teva Pharmaceuticals has been a good defensive play during the severe downturn in the market. mark for My Articles similar articles
The Motley Fool
July 27, 2010
Brian Orelli
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. mark for My Articles similar articles
Financial Planning
September 1, 2008
Andrew Ackerman
SEC Probes Wachovia The Securities and Exchange Commission enforcement staff has notified Wachovia Bank that they may recommend the SEC file charges against it, as a result of an investigation into alleged anti-competitive bidding practices. mark for My Articles similar articles
The Motley Fool
May 12, 2011
Brian Orelli
Teva's Mixed Bag Diversification sure helps. mark for My Articles similar articles
The Motley Fool
December 1, 2009
Brian Orelli
Abbott Makes All the Right Moves Hot off its cholesterol win over Merck, Abbott Labs is playing it safe with another cholesterol drug, TriCor. mark for My Articles similar articles
The Motley Fool
March 4, 2005
Rich Duprey
Flamel Flames Out Again Nanotech regains rights to herpes treatment as partnership with pharma Biovail fails. mark for My Articles similar articles
The Motley Fool
November 5, 2004
Roger Nusbaum
The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy. mark for My Articles similar articles
The Motley Fool
November 27, 2006
Brian Lawler
Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs. mark for My Articles similar articles
The Motley Fool
February 27, 2009
Brian Orelli
Double Approvals, Accelerated Growth Genzyme gets a pair of approvals -- one from each side of the Atlantic -- for two different products. mark for My Articles similar articles
The Motley Fool
April 13, 2010
Brian Orelli
Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development. mark for My Articles similar articles
The Motley Fool
February 13, 2008
Brian Orelli
Teva Tears It Up After a stellar 2006 because of exclusive launches of some big-time generics, it seemed like Teva Pharmaceuticals would have a heck of a time keeping the pace up in 2007. Apparently, that fear was unwarranted. mark for My Articles similar articles
The Motley Fool
March 28, 2006
Charly Travers
"60 Minutes" Blew It The venerable news show stumbles in its coverage of short selling. While some CEOs might draw attention away from their businesses' performance by invoking the short-seller boogeyman, rational investors should resist that distraction and focus on the crystal-clear fundamentals. mark for My Articles similar articles
The Motley Fool
June 28, 2011
Eric Bleeker
Where Is Teva Pharmaceuticals Finding Growth? Teva should see its sales continue to climb, especially in already booming international markets. mark for My Articles similar articles
The Motley Fool
August 10, 2010
Brian Orelli
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow. mark for My Articles similar articles
The Motley Fool
June 6, 2005
Stephen D. Simpson
"Bad News" for Teva? Yawn... Be ready to act when the market overreacts. For those investors who think that Teva Pharmaceutical will maintain its top-dog status in the generics world, this is just a blip on the scope and/or the opportunity to build a position. mark for My Articles similar articles
The Motley Fool
August 29, 2008
Brian Orelli
Can Health-Care Dividends Hold Up? As many health-care companies' share prices drop, their dividend yields have become strikingly attractive. The big question, though, is whether these dividends can hold up. mark for My Articles similar articles
Registered Rep.
May 10, 2007
Kristen French
SEC Impostors on the Loose The SEC issued an alert to securities industry firms, warning them to keep an eye out for impostors -- individuals pretending to work for the SEC. mark for My Articles similar articles
The Motley Fool
August 17, 2010
Travers & Jayson
How Long Can Biovail Last? Stop obsessing about the science. mark for My Articles similar articles
CFO
October 1, 2002
Alix Nyberg
Regulation: Pitt and the Pendulum The kinder, gentler SEC Pitt envisioned vanished faster than you can say Arthur Andersen. Can he run a tougher, meaner agency? mark for My Articles similar articles
The Motley Fool
August 13, 2008
Dan Dzombak
3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Constellation Energy... Manitowoc... Biovail... mark for My Articles similar articles
The Motley Fool
August 11, 2008
Rich Duprey
The Auction-Rate Thaw Turns to a Flood Settlements by big investment banks may finally inundate the frozen market with cash. mark for My Articles similar articles